Sodium-Glucose Cotransporter-2 Inhibitor for Renal Function Preservation in Patients with Type 2 Diabetes Mellitus: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement

Diabetes is a leading cause of end-stage renal disease. Therefore, prevention of renal dysfunction is an important treatment goal in the management of diabetes. The data of landmark cardiovascular outcome trials of sodium-glucose cotransporter-2 (SGLT2) inhibitor showed profound reno-protective effe...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Diabetes Metab J
Glavni autori: Oh, Tae Jung, Moon, Ju-Young, Hur, Kyu Yeon, Ko, Seung Hyun, Kim, Hyun Jung, Kim, Taehee, Lee, Dong Won, Moon, Min Kyong
Format: Artigo
Jezik:Inglês
Izdano: Korean Diabetes Association 2020
Teme:
Review
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7453978/
https://ncbi.nlm.nih.gov/pubmed/32856800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4093/dmj.2020.0172
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items